Toll-like receptor 9 (TLR9) (TLR9)

Toll-like receptor 9 (TLR9) is a critical pattern recognition receptor of the innate immune system, primarily localized within the endosomal compartments of plasmacytoid dendritic cells and B cells [1, 15]. It specifically recognizes unmethylated cytosine-phosphate-guanine (CpG) DNA motifs, which are prevalent in bacterial and viral genomes but rare in vertebrate DNA, thereby serving as a key sensor for microbial pathogens [4, 15]. Upon activation, TLR9 initiates a signaling cascade through the adaptor protein MyD88, leading to the activation of transcription factors like NF-κB and IRF7, which drive the production of Type I interferons and pro-inflammatory cytokines [1, 7]. The receptor's structure includes leucine-rich repeats for ligand binding and a cytoplasmic TIR domain for signal transduction [15]. In the context of disease, TLR9 plays a dual role; its activation can promote anti-tumor immunity by transforming "cold" tumors into "hot" ones, while its dysregulation or recognition of self-DNA is implicated in the pathogenesis of autoimmune diseases like systemic lupus erythematosus [4, 13, 20]. Therapeutic strategies involve the use of synthetic CpG oligodeoxynucleotide agonists, such as vidutolimod and tilsotolimod, to enhance vaccine efficacy and cancer immunotherapy [11, 18]. Conversely, antagonists like hydroxychloroquine and IMO-8400 are utilized or investigated to dampen excessive inflammation in autoimmune and chronic inflammatory conditions [2, 5, 6].

Other names

CD289Toll-like receptor 9TLR9 signaling pathwayTLR9-MyD88 pathway

TLR9 agonists bind to the receptor in endosomal compartments, triggering MyD88-dependent signaling that activates NF-κB and IRF7, leading to the production of pro-inflammatory cytokines and Type I interferons. Conversely, TLR9 antagonists inhibit this pathway by blocking ligand binding or preventing endosomal acidification, thereby reducing inflammatory responses in autoimmune conditions.